Bijoy Hans Ltd to consider acquisition of Sushodha Institute and share‑swap in board meeting on July 11

What Bijoy Hans Ltd announced

Bijoy Hans Ltd (now Arvaya Healthcare Limited) filed a prior intimation with the BSE on 6 July 2026, stating that its Board of Directors will convene on Saturday, 11 July 2026. The agenda covers an acquisition, related‑party transactions, and several equity‑raising proposals, including a share‑swap and a rights issue. The filing also notes that the trading window will be closed from 1 July 2026 until 48 hours after the declaration of the unaudited financial results for the first quarter ended 30 June 2026.

Acquisition of Sushodha Institute of Gastroenterology Private Limited

The primary item on the agenda is the acquisition of Sushodha Institute of Gastroenterology Private Limited. No financial terms, such as purchase price or payment structure, are disclosed in the filing. The acquisition is presented alongside a material related‑party transaction involving Mr. Bidari Kotresh Anilkumar, though the nature of that transaction is not detailed.

Share‑swap and rights issue proposals

The Board will also evaluate a proposal to issue equity shares on a preferential basis for consideration other than cash (share‑swap). This suggests that the company may use its own shares as currency for the acquisition or other strategic purposes. In addition, a rights issue is proposed, whereby existing shareholders could be offered securities on a rights basis, subject to regulatory approvals. The filing mentions the intention to constitute a Right Issue Committee to oversee the process.

Key facts at a glance

Why this matters for investors

The announced agenda signals a potential expansion of Bijoy Hans Ltd’s business through the acquisition of a gastroenterology institute. If approved, the deal could diversify the company’s service portfolio. The related‑party transaction with Mr. Bidari Kotresh Anilkumar may raise governance scrutiny, as material related‑party dealings require shareholder approval under SEBI regulations. The share‑swap and rights issue proposals indicate that the company may seek to fund the acquisition and strengthen its capital base without immediate cash outflow, which could lead to dilution of existing shareholders if new shares are issued. The closure of the trading window ahead of the board meeting is a standard compliance step to prevent insider trading.

Conclusion

Bijoy Hans Ltd’s board meeting on 11 July 2026 will decide on a strategic acquisition, a material related‑party transaction, and two equity‑raising mechanisms. While the filing confirms the agenda, it does not disclose financial specifics of the acquisition or the terms of the share‑swap and rights issue. Shareholders will need to await the Board’s resolutions and any subsequent shareholder approvals to understand the full impact on the company’s capital structure and operations.